Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno C Medeiros

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Cancer Chemotherapy and Pharmacology|November 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human studyCarla Biesdorf, Xiaowen Guan, Satya R Siddani, et al.
Leukemia & Lymphoma|May 2, 2022
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemiaThomas Prebet, Aaron D Goldberg, Joseph G Jurcic, et al.
Oncotarget|October 13, 2016
Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patientsLene Sofie Granfeldt Østgård, Mette Nørgaard, Henrik Sengeløv, et al.
American Journal of Hematology|September 28, 2010
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experienceHolbrook E Kohrt, Samit Patel, Michelle Ho, et al.
Leukemia Research|September 29, 2009
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)Bruno C Medeiros, Holbrook E Kohrt, Daniel A Arber, et al.
Plos One|July 11, 2019
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosminRupa Narayan, Niclas Olsson, Lisa E Wagar, et al.
American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|November 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human studyCarla Biesdorf, Xiaowen Guan, Satya R Siddani, et al.
Leukemia & Lymphoma|May 2, 2022
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemiaThomas Prebet, Aaron D Goldberg, Joseph G Jurcic, et al.
Oncotarget|October 13, 2016
Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patientsLene Sofie Granfeldt Østgård, Mette Nørgaard, Henrik Sengeløv, et al.
American Journal of Hematology|September 28, 2010
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experienceHolbrook E Kohrt, Samit Patel, Michelle Ho, et al.
Leukemia Research|September 29, 2009
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)Bruno C Medeiros, Holbrook E Kohrt, Daniel A Arber, et al.
Plos One|July 11, 2019
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosminRupa Narayan, Niclas Olsson, Lisa E Wagar, et al.
American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
Pageof 11